NCT06896617 Impact of the Presence of the Corpus Luteum on Pregnancies Obtained Through Frozen Embryo Transfer(FET)
| NCT ID | NCT06896617 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Fundacion Clinic per a la Recerca Biomédica |
| Condition | Infertilities |
| Study Type | INTERVENTIONAL |
| Enrollment | 334 participants |
| Start Date | 2025-02-01 |
| Primary Completion | 2026-11-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 334 participants in total. It began in 2025-02-01 with a primary completion date of 2026-11-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In pregnancies achieved through programmed frozen embryo transfer cycle (PC-FET) and modified natural frozen embryo transfer (mNC-FET), to determine whether there are differences in endothelial and placental function, maternal cardiovascular function, fetal growth and fetal cardiovascular and cerebral programming and to assess whether there is an association between these differences and the plasma concentrations of the main secretion products of the Corpus Luteum (CL) with vasoactive and angiogenic action.
Eligibility Criteria
Inclusion Criteria: * Female patients 18- 37 years old (both included) at the time of oocyte retrieval and less than 41 years of age at the time of embryo transfer. * Regular menstrual cycles between 24 and 35 days. * Availability of cryopreserved blastocysts from own gametes * Indication for single embryo transfer. * Patients who will be included in the LUTI study are candidates for either of the two procedures under study, and will have no contraindications for either procedure. Exclusion Criteria: * Recurrent pregnancy loss (3 or more). * Recurrent implantation failure in previous IVF treatments (3 or more unsuccessful embryo transfers). . * Diagnosis of polycystic ovarian syndrome, diabetes mellitus, chronic arterial hypertension, maternal heart disease and autoimmune diseases (Systemic Lupus Erythematosus (SLE) or Antiphospholipid syndrome (APS)). * Active treatment with aspirin, heparin or other anticoagulant therapy, antihypertensives or other drugs used to treat circulation or coagulation disorders . * Indication for PGT (Preimplantation Genetic Testing). * Multiple pregnancy.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06896617 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 41 Years, studying Infertilities. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06896617 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06896617 currently recruiting?
Yes, NCT06896617 is actively recruiting participants. Contact the research team at burunat@recerca.clinic.cat for enrollment information.
Where is the NCT06896617 trial being conducted?
This trial is being conducted at Barcelona, Spain.
Who is sponsoring the NCT06896617 clinical trial?
NCT06896617 is sponsored by Fundacion Clinic per a la Recerca Biomédica. The trial plans to enroll 334 participants.